News
All News
Publications
All PublicationsPharmTechPharmTech Europe
Multimedia
All VideosAsk the ExpertBehind The HeadlinesDrug Digest VideosDrug Solutions Podcast
Conferences
Conference CoverageConference Listing
More
Webcasts
Resources
ICH Q9 Revision: A Comprehensive Resource on Quality Risk ManagementPartnersPeer-Reviewed ResearchPharmTech ProductsPharma InsightsSponsored PodcastsSponsored VideosSponsored eBooksState of the ScienceWhitepapers

Subscribe

  • News
  • Publications
  • Multimedia
  • Conferences
  • Webcasts
  • Resources
  • Subscribe
  • Analytics
    • Bio/Pharmaceutical Analysis Techniques
    • Laboratory Equipment and Instruments
  • Data and Artificial Intelligence
  • Dosage Forms
    • Solid/Semi-Solid Dosage
    • Specialty Dosage Drugs
    • Parenterals and Injectables
    • Inhalation Drugs
  • Drug Development
    • Intellectual Property and Patents
    • Process and Scaling
    • APIs and Excipients
    • Ingredients
    • Formulation and Drug Delivery
  • Manufacturing
    • Aseptic/Sterile Processing
    • Equipment
    • Process and Automation
    • Manufacturing, Parenterals and Injectables
    • Manufacturing, Biosimilars and Biobetters
    • Manufacturing, Inhalation Drugs
    • Manufacturing, Solid and Semi-Solid Dosage Drugs
    • Manufacturing, Cell Therapies
    • Manufacturing, Biologic Drugs
    • Supply Chain
    • Manufacturing, Gene Therapies
    • Packaging and Distribution
  • Outsourcing
    • Contract Research Services
    • Contract Analytical Services
    • Contract Development Services
    • Regulatory Consulting
    • Logistics and Distribution
    • Contract Manufacturing Services
  • Quality Systems
    • Ask the Expert
    • Quality Assurance/Quality Control
    • Regulatory Oversight and Compliance
Spotlight -
Analytics|
Dosage Forms|
Drug Development|
Manufacturing|
Outsourcing|
Quality Systems
Advertisement

Jean Domoradzki

Advertisement

EHS specialist at Dow Corning Corporation, Auburn, MI

Articles by Jean Domoradzki

Establishing Limits for Dermal Absorption of Elemental Impurities

ByAndrew Teasdale,Katherine Ulman,Phyllis Walsh,Jean Domoradzki
September 2nd 2015

Current guidance for absorption of elemental impurities does not address dermal exposure, resulting in a simplistic approach to limit setting.

Advertisement

Latest Updated Articles

  • Establishing Limits for Dermal Absorption of Elemental Impurities
    Establishing Limits for Dermal Absorption of Elemental Impurities

    Published: September 2nd 2015 | Updated:



Advertisement
Advertisement

Trending on Pharmaceutical Technology

1

CNPV Deep Dive: Perspectives on Accelerated FDA Review From the C-Suite to the Manufacturing Floor

2

Multi-Compendial Compliance for Pharmaceutical Excipients–Part 1: A Practical Application of Specification Equivalence

3

De-risking Biologic Development: Engineering Flexibility from Early Development to Launch

4

Behind the Headlines Episode 30: 2026 Wish List

5

Momentum and Automation Driving Pharma Innovation and Digitalization Through 2026

  • About Us
  • Advertise
  • Contact Us
  • Editorial Info
  • Editorial Advisory Board
  • Do Not Sell My Personal Information
  • Privacy Policy
  • Terms and Conditions
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

609-716-7777

Brand Logo

© 2025 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us